New Program to Help Promote Good Bone Health In Advanced Prostate Cancer Patients On Long-Term Androgen Deprivation Therapy
Watson Pharmaceuticals, Inc. today announced a new program encouraging health professionals to help maintain the bone health of prostate cancer patients who are on long-term androgen deprivation therapy (ADT). Nearly two million men are receiving ADT, a palliative treatment for prostate cancer that, while highly effective and considered the gold therapy, can cause bone loss and increase a man’s risk for osteoporosis.